PTMA
Description
The PTMA (prothymosin alpha) is a protein-coding gene located on chromosome 2.
The PTMA gene encodes prothymosin alpha, a protein that gives rise to the peptide thymosin α1. Thymosin α1, a 28-amino acid fragment of prothymosin alpha, was the first peptide isolated from Thymosin Fraction 5, a mixture of peptides that have shown immune-boosting effects. It's believed to be a key component of Thymosin Fraction 5, responsible for its ability to restore immune function in animals lacking thymus glands. Thymosin α1 has been shown to enhance cell-mediated immunity in both humans and animals. It's currently approved in 35 developing countries to treat Hepatitis B and C, and is used to strengthen the immune system in various diseases. Research suggests potential benefits in cystic fibrosis, sepsis, respiratory distress, peritonitis, cytomegalovirus infection, tuberculosis, severe acute respiratory syndrome (SARS), lung infections in critically ill patients, chronic hepatitis B, and even cancer treatment (in conjunction with chemotherapy).
Prothymosin alpha may regulate immune function by protecting against certain opportunistic infections.
PTMA is also known as TMSA.
Associated Diseases
- X-linked endothelial corneal dystrophy
- X-linked corneal dermoid
- autosomal dominant keratitis
- granular corneal dystrophy type I
- Schnyder corneal dystrophy
- Thiel-Behnke corneal dystrophy
- congenital primary aphakia
